Clinical Trial Update: Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label treatment extension study of SAR245408 or SAR245409 as monotherapy or in combination therapy in malignant neoplasms completed; results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasm

Drugs mentioned

• SAR245408
• SAR245409

Snippet

Sponsor: Sanofi | Conditions: Neoplasm Malignant | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-06-11